December 2024 Research Roundtable: GLP-1 Agonists and Obesity, Lymphedema, and Lipedema

A rapid-fire Research Roundtable filled with questions about #GLP1 agonists, obesity, lymphedema, and lipedema were expertly answered by Dr. Leopold Cobos Salinas, diplomate of the American Board of Obesity Medicine and board-certified in endocrinology and internal medicine. Starting with “What are GLP-1s?” and the differences between terzepatide and semaglutide, Dr. Cobos Salinas explained the diseases GLP-1 agonists are prescribed for, what they do in the body, and both the side effects and positive impacts of these medications. Concerns surrounding the loss of muscle mass, the notable reduction of inflammation, and how weight loss can “unmask” previously hidden fibrotic nodules were of particular interest. The conversation also covered topics such as the differentiations between compound medications and the concept of microdosing. Personal accounts of patients dislodged from weight loss plateaus and many who have experienced improved quality of life were balanced by the need for further study and the challenge of prohibitive cost when these medications are not covered by insurance. Dr. Cobos Salinas is leading the way in education.  He considers #lipedema a grossly underdiagnosed condition and is devoted to raising awareness and providing support to these patients at his Laredo, Texas, practice. ---------- This Roundtable was originally recorded live on December 2, 2024, and has been edited for time. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of Lympha Press. The content is for educational purposes only. Thank you to ‪‪‪@brendaviolamedia2024‬ for moderating! 📚 MORE INFORMATION: This Roundtable is presented by ‪‪‪@Lympha_Press‬. Learn more about #LymphaPress and our advanced pneumatic #compressiontherapy here: https://lymphapress.com/ Register for our upcoming virtual events here: https://linktr.ee/LymphaPress